Synonym
BN 50739; BN50739; BN-50739.
IUPAC/Chemical Name
9-(2-chlorophenyl)-14-{2-[(3,4-dimethoxyphenyl)sulfanyl]ethanethioyl}-3-methyl-17-thia-2,4,5,8,14-entaazatetracyclo[8.7.0.0^{2,6}.0^{11,16}]heptadeca-1(10),3,5,8,11(16)-pentaene
InChi Key
MRVWRDZEYURFSW-UHFFFAOYSA-N
InChi Code
InChI=1S/C28H26ClN5O2S3/c1-16-31-32-24-13-30-27(18-6-4-5-7-20(18)29)26-19-10-11-33(14-23(19)39-28(26)34(16)24)25(37)15-38-17-8-9-21(35-2)22(12-17)36-3/h4-9,12H,10-11,13-15H2,1-3H3
SMILES Code
CC1=NN=C2CN=C(C3=CC=CC=C3Cl)C(C4=C(S5)CN(C(CSC6=CC=C(OC)C(OC)=C6)=S)CC4)=C5N12
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
596.18
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Baker KE, Curtis MJ. Protection against ventricular fibrillation by the PAF antagonist, BN-50739, involves an ischaemia-selective mechanism. J Cardiovasc Pharmacol. 1999 Sep;34(3):394-401. PubMed PMID: 10470998.
2: Kintner DB, Fitzpatrick JH Jr, Gilboe DD. Hyperglycemic damage to mitochondrial membranes during cerebral ischemia: amelioration by platelet-activating factor antagonist BN 50739. J Neurochem. 1997 Sep;69(3):1219-27. PubMed PMID: 9282946.
3: Sun D, Gilboe DD. Effect of the platelet-activating factor antagonist BN 50739 and its diluents on mitochondrial respiration and membrane lipids during and following cerebral ischemia. J Neurochem. 1994 May;62(5):1929-38. PubMed PMID: 8158141.
4: Ranaut K, Singh M. BN-50739: a PAF antagonist and limitation of myocardial infarct size. Methods Find Exp Clin Pharmacol. 1993 Jan-Feb;15(1):9-14. PubMed PMID: 8479250.
5: Koltai M, Tosaki A, Hosford D, Esanu A, Braquet P. Effect of BN 50739, a new platelet activating factor antagonist, on ischaemia induced ventricular arrhythmias in isolated working rat hearts. Cardiovasc Res. 1991 May;25(5):391-7. PubMed PMID: 1855244.
6: Rabinovici R, Yue TL, Farhat M, Smith EF 3rd, Esser KM, Slivjak M, Feuerstein G. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist. J Pharmacol Exp Ther. 1990 Oct;255(1):256-63. PubMed PMID: 2213560.
7: Yue TL, Farhat M, Rabinovici R, Perera PY, Vogel SN, Feuerstein G. Protective effect of BN 50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits. J Pharmacol Exp Ther. 1990 Sep;254(3):976-81. PubMed PMID: 2395125.
8: Yue TL, Rabinovici R, Farhat M, Feuerstein G. Pharmacologic profile of BN 50739, a new PAF antagonist in vitro and in vivo. Prostaglandins. 1990 May;39(5):469-80. PubMed PMID: 2353116.
9: Karasawa A, Rochester JA, Lefer AM. Beneficial actions of BN 50739, a new PAF receptor antagonist, in murine traumatic shock. Methods Find Exp Clin Pharmacol. 1990 May;12(4):231-7. PubMed PMID: 2165204.
